ArticleCarcinogenesis2010
Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells.
Article in Carcinogenesis, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it, 128 citations in OpenAlex.
- Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics.Pharmacology & therapeutics · 2019Pooled it
- Regulation of β-cell death by ADP-ribosylhydrolase ARH3 via lipid signaling in insulitis.Cell communication and signaling : CCS · 2024Article
- CD36: The Bridge between Lipids and Tumors.Molecules (Basel, Switzerland) · 2024Review
- A Survey of Fatty Acid Content of the Male Reproductive System in Mice Supplemented With Arachidonic Acid.Journal of lipids · 2024Article
- The effectiveness of omega-3 fatty acids on health outcomes in women with breast cancer: A systematic review.Food science & nutrition · 2023Review
- Signaling pathways in cancer metabolism: mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2023Review
- Epigenetic Modifications Induced by the Gut Microbiota May Result from What We Eat: Should We Talk aboutMetabolites · 2023Review
- DNA Methylation in Cancer: Epigenetic View of Dietary and Lifestyle Factors.Epigenetics insights · 2023Review
- Article
- Article
- Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges.Frontiers in pharmacology · 2022Review
- Successive High-Resolution (HAnalytical chemistry · 2021Article
- Polar Lipids of CommercialFoods (Basel, Switzerland) · 2021Article
- Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention.Clinical epigenetics · 2021Article
- Targeting ferroptosis in breast cancer.Biomarker research · 2020Review
- Chromatin dynamics and histone modifications in intestinal microbiota-host crosstalk.Molecular metabolism · 2020Review
- Nutrigenomics and Breast Cancer: State-of-Art, Future Perspectives and Insights for Prevention.Nutrients · 2020Review
- Gene Promoter Hypermethylation Detected in Sputum Predicts FEVAmerican journal of respiratory and critical care medicine · 2018Article
- Impact of dietary gut microbial metabolites on the epigenome.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2018Review
- Implications of dietary ω-3 and ω-6 polyunsaturated fatty acids in breast cancer.Experimental and therapeutic medicine · 2018Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The polycomb group (PcG) protein, enhancer of zeste homologue 2 (EZH2), is overexpressed in several human malignancies including breast cancer. Aberrant expression of EZH2 has been associated with metastasis and poor prognosis in cancer patients. Despite the clear role of EZH2 in oncogenesis and therapy failure, not much is known about chemotherapeutics and chemopreventive agents that can suppress its expression and activity. Here, we show that dietary omega-3 (omega-3) polyunsaturated fatty acids (PUFAs) can regulate the expression of EZH2 in breast cancer cells. The treatment of breast cancer cells with omega-3 PUFAs, but not omega-6 PUFAs, led to downregulation of EZH2. Studies using proteosome inhibitor MG132 suggested that omega-3 PUFAs induce degradation of the PcG protein EZH2 through posttranslational mechanisms. Furthermore, downregulation of EZH2 by omega-3 PUFAs was accompanied by a decrease in histone 3 lysine 27 trimethylation (H3K27me3) activity of EZH2 and upregulation of E-cadherin and insulin-like growth factor binding protein 3, which are known targets of EZH2. Treatment with omega-3 PUFAs also led to decrease in invasion of breast cancer cells, an oncogenic phenotype that is known to be associated with EZH2. Thus, our studies suggest that the PcG protein EZH2 is an important target of omega-3 PUFAs and that downregulation of EZH2 may be involved in the mediation of anti-oncogenic and chemopreventive effects of omega-3 PUFAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.